Press Releases
Journal of Clinical Investigations Just a spoonful of metformin helps the medicine go down
Diffuse intrinsic pontine glioma (DIPG) is a devastating brain tumor with a need for novel therapies. So far, monotherapies have failed to prolong survival for these patients, and combinatorial strategies have often shown severe, dose-limiting toxicities.
Pediatric Neurosurgery Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas
Diffuse intrinsic pontine gliomas (DIPGs) are high-grade gliomas (HGGs) that occur primarily in children, and represent a leading cause of death in pediatric patients with brain tumors with a median overall survival of only 8–11 months.
Clinical Cancer Research Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003
PNOC003 is a multicenter precision medicine trial for children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
Neuro-Oncology DIPG-31 Prognostic and predictive biomarkers for H3K27M-altered diffuse intrinsic pontine glioma from PNOC003
Diffuse intrinsic pontine glioma (DIPG) is a fatal brain tumor. Herein, we report on novel prognostic and predictive genomic biomarkers identified in PNOC003, a multi-center precision medicine trial for children and young adults diagnosed with DIPG.
Journal of Neurosurgery Liquid biopsy for diffuse intrinsic pontine glioma: an update
Diffuse intrinsic pontine glioma (DIPG), otherwise known as diffuse midline glioma with H3K27M mutation, is a devastating brainstem glioma without a cure. Efforts are currently underway to better optimize molecular diagnoses through biological sampling, which today remains largely limited to surgical biopsy sampling.
International Journal of Cancer A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from PNOC
This clinical trial evaluated whether whole exome sequencing (WES) and RNA sequencing (RNAseq) of paired normal and tumor tissues could be incorporated into a personalized treatment plan for newly diagnosed patients (<25 years of age) with diffuse intrinsic pontine glioma (DIPG).
DIPG-76 PNOC-003: trial for children with diffuse intrinsic pontine glioma: preliminary experience with multi-agent personalized therapy recommendations
New therapies for children with diffuse intrinsic pontine glioma (DIPG) are greatly needed.